Lumvoa is an FDA approved treatment for Thyroid Eye Disease (TED), regardless of disease activity or duration. It is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor that targets the underlying disease pathway involved in orbital inflammation and tissue remodeling associated with TED. As a new therapeutic option in this rare autoimmune condition, Lumvoa has the potential to reshape the treatment landscape for patients with thyroid eye disease. For clinical trial and first-to-file teams, monitoring its market adoption, exclusivity timeline, and availability will be important, as it may emerge as a relevant comparator in ophthalmology and autoimmune disease studies.